Trial reportBMC anesthesiology2026
Effects of remote ischemic preconditioning on postoperative gastrointestinal function in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled trial.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPostoperative gastrointestinal function is one of the important factors influencing the prognosis of off-pump coronary artery bypass grafting (OPCAB) patients. Remote ischemic preconditioning (RIPC) is a noninvasive intervention that may offer multiorgan protection. This study aimed to evaluate the impact of preoperative RIPC on postoperative gastrointestinal function and clinical outcomes in OPCAB patients.
methodsThis prospective, assessor- and statistician-blinded, sham-controlled, randomized clinical trial included 106 patients scheduled to undergo elective OPCAB. They were randomly assigned to the RIPC (n = 53) or sham-RIPC (n = 53) group. The RIPC group received bilateral upper limb ischemia/reperfusion cycles (200 mmHg, 5-min ischemia/5-min reperfusion, repeated for 5 cycles) twice daily for 3 consecutive preoperative days. The primary outcome was the incidence of postoperative gastrointestinal intolerance (POGI), defined as an I-FEED score of 3-5 within 7 days postoperatively. The secondary outcomes included markers of intestinal injury (intestinal fatty acid-binding protein (I-FABP)), systemic inflammation (interleukin-6 (IL-6), C-reactive protein (CRP)), and S-100 protein beta subunit (S-100β). The exploratory outcomes comprised gut microbiota analysis and other clinical parameters.
resultsThe incidence of POGI was lower in the RIPC than in the sham-RIPC group (35.4% vs. 56.5%, P = 0.040). The postoperative serum levels of I-FABP, IL-6, CRP, and S-100β were also lower in the RIPC group. Moreover, the relative abundance of Gemella and Dorea decreased in the RIPC group postoperatively. Notably, the abundance of Gemella showed a positive correlation with the postoperative levels of I-FABP and IL-6, whereas that of Dorea exhibited a positive correlation with the postoperative I-FABP levels.
conclusionsThe preoperative application of RIPC was associated with a lower risk of POGI, with no observed safety concerns. This effect of RIPC may be related to attenuated intestinal mucosal injury, reduced systemic inflammation, and potential modulation of the gut microbiota.
trial registrationThis study was registered on May 30, 2024 (ChiCTR2400085044).
Indexed as
Identifiers
42265607What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.